Table 2.
Association of programmed cell death protein 1 (PD1) expression by tumor cells with clinicopathologic parameters in 182 patients with esophageal adenocarcinoma
| Factor | Adenocarcinoma (n = 168) n (%) | PD1+ cancer cells (n = 130) n (%) | PD1− cancer cells (n = 38) n (%) | p value |
|---|---|---|---|---|
| Tumor stage | ||||
| High-grade dysplasia | 4 (2.4) | 1 (25) | 3 (75) | <0.001 |
| pT1a | 13 (7.7) | 3 (23.1) | 10 (76.9) | |
| pT1b | 20 (11.9) | 6 (30) | 14 (70) | |
| pT2 | 49 (29.2) | 45 (91.8) | 4 (8.2) | |
| pT3 | 77 (45.8) | 73 (94.8) | 4 (5.2) | |
| pT4 | 5 (3) | 2 (40) | 3 (60) | |
| Lymph node status | ||||
| pNx | 13 (7.7) | 0.004 | ||
| pN0 | 61 (36.3) | 38 (62.3) | 23 (37.7) | |
| pN1 | 31 (18.5) | 27 (87.1) | 4 (12.9) | |
| pN2 | 26 (15.5) | 22 (84.6) | 4 (15.4) | |
| pN3 | 37 (22) | 33 (89.2) | 4 (10.8) | |
| Histologic grading | ||||
| G1 | 7 (4.2) | 5 (71.4) | 2 (28.6) | 0.225 |
| G2 | 74 (44) | 53 (71.6) | 21 (28.4) | |
| G3 | 87 (51.8) | 72 (82.8) | 15 (17.2) | |
| Neoadjuvant therapy | ||||
| Yes | 63 (37.5) | 53 (84.1) | 10 (15.9) | 0.105 |
| Total resection | ||||
| Yes | 145 (86.3) | 111 (76.6) | 34 (23.4) | 0.519 |
| No | 23 (13.7) | 19 (82.6) | 4 (17.4) | |
| Siewert classification | ||||
| AEG 1 | 101 (60.1) | 72 (71.3) | 29 (28.7) | 0.058 |
| AEG 2 | 44 (26.2) | 39 (88.6) | 5 (11.4) | |
| AEG 3 | 23 (13.7) | 19 (82.6) | 4 (17.4) | |
| PD1 expression by tumor cells | ||||
| 0 (0%) | 38 (22.6) | |||
| 1+ (5–25%) | 36 (21.4) | |||
| 2+ (26–50%) | 30 (17.9) | |||
| 3+ (51–75%) | 43 (25.6) | |||
| 4+ (76–100%) | 21 (12.5) | |||
PD1 programmed cell death protein 1, AEG adenocarcinoma of the esophagogastric junction